

**eTable.** Coefficients obtained when fitting the model reported originally<sup>4</sup> to the analysis set used in the present study. As in the original report, effect estimates are from models adjusted for age and sex.

Gene <sup>1</sup> (rs ID), genotypic model <sup>2</sup>	Original report		Present study			
	OR	(95% CI)	P	OR	(95% CI)	P
CDC42 (rs2056974), d	2.09	(1.24-3.52)	5.60E-03	2.10	(1.25-3.54)	5.1E-03
DCC <sub>1</sub> (rs1160400), r <sup>3</sup>	7.75	(1.06-57.01)	4.40E-02	6.63	(0.82-53.35)	7.5E-02
DCC <sub>2</sub> (rs1466373), d	2.03	(1.14-3.64)	1.70E-02	2.05	(1.14-3.68)	1.6E-02
DCC <sub>3</sub> (rs1502219), a	2.42	(1.55-3.79)	1.00E-04	2.43	(1.56-3.80)	9.4E-05
DCC <sub>4</sub> (rs4334396), r	14.33	(3.92-52.34)	5.60E-05	14.38	(3.94-52.51)	5.5E-05
DCC <sub>5</sub> (rs7506794), a	0.07	(0.03-0.19)	1.60E-07	0.07	(0.03-0.19)	1.6E-07
EFNA5 <sub>1</sub> (rs152580), r	2.78	(1.49-5.19)	1.30E-03	2.77	(1.49-5.17)	1.3E-03
EFNA5 <sub>2</sub> (rs252802), d	2.94	(1.58-5.47)	7.00E-04	2.96	(1.59-5.52)	6.5E-04
EFNA5 <sub>3</sub> (rs6868410), r	0.67	(0.07-7.00)	7.40E-01	0.68	(0.07-7.12)	7.5E-01
EPHA4 (rs10498114), d	0.38	(0.21-0.68)	1.20E-03	0.38	(0.21-0.68)	1.2E-03
EPHB1 <sub>1</sub> (rs11917038), a	0.93	(0.49-1.76)	8.20E-01	0.92	(0.49-1.75)	8.0E-01
EPHB1 <sub>2</sub> (rs1404577), r	0.19	(0.06-0.66)	8.60E-03	0.19	(0.06-0.66)	8.6E-03
EPHB1 <sub>3</sub> (rs6793828), r	0.48	(0.24-0.95)	3.50E-02	0.47	(0.23-0.94)	3.2E-02
EPHB1 <sub>4</sub> (rs9865620), d	0.24	(0.13-0.45)	6.80E-06	0.24	(0.13-0.45)	7.0E-06
EPHB2 (rs11800828), d	1.89	(1.07-3.35)	3.00E-02	1.88	(1.06-3.33)	3.1E-02
FYN <sub>1</sub> (rs11153311), a	0.36	(0.20-0.64)	5.50E-04	0.36	(0.20-0.64)	5.0E-04
FYN <sub>2</sub> (rs809193), a	2.31	(1.48-3.62)	2.40E-04	2.31	(1.48-3.61)	2.5E-04
GSK3B (rs3108749), a	0.36	(0.20-0.66)	1.00E-03	0.36	(0.20-0.66)	9.0E-04
PAK7 <sub>1</sub> (rs1033470), d	2.58	(1.51-4.43)	5.70E-04	2.58	(1.50-4.42)	5.8E-04
PAK7 <sub>2</sub> (rs219861), d	0.53	(0.30-0.93)	2.60E-02	0.53	(0.30-0.93)	2.7E-02
PLXNA2 <sub>1</sub> (rs2782934), r	0.19	(0.07-0.51)	1.00E-03	0.19	(0.07-0.51)	1.1E-03
PLXNA2 <sub>2</sub> (rs6685511), d	2.26	(1.21-4.22)	1.10E-02	2.26	(1.21-4.22)	1.0E-02
PLXNC1 <sub>1</sub> (rs10507033), r	0.02	(0.003-0.16)	1.70E-04	0.02	(0.003-0.16)	1.7E-04
PLXNC1 <sub>2</sub> (rs865569), r	21.64	(2.41-194.15)	6.00E-03	21.53	(2.40-193.08)	6.1E-03
PPP3CA (rs2732504), d	0.48	(0.29-0.82)	6.30E-03	0.49	(0.29-0.82)	7.2E-03
RAC2 (rs9610680), a	1.95	(1.19-3.21)	8.20E-03	1.97	(1.20-3.24)	7.5E-03
RRAS2 (rs2970334), d	0.32	(0.17-0.60)	4.20E-04	0.33	(0.17-0.61)	5.3E-04
SEMA5A <sub>1</sub> (rs1512508), d	2.38	(1.27-4.47)	6.70E-03	2.39	(1.28-4.48)	6.5E-03
SEMA5A <sub>2</sub> (rs40701), r	0.98	(0.39-2.47)	9.60E-01	0.99	(0.39-2.51)	9.8E-01
SLIT3 <sub>1</sub> (rs11746295), r	0.14	(0.03-0.58)	6.70E-03	0.14	(0.03-0.58)	7.0E-03
SLIT3 <sub>2</sub> (rs1979923), r	0.2	(0.08-0.53)	1.20E-03	0.21	(0.08-0.54)	1.3E-03
SLIT3 <sub>3</sub> (rs884787), d	3.48	(1.44-8.43)	5.80E-03	3.49	(1.44-8.46)	5.6E-03
UNC5C (rs6820369), d	2.22	(1.03-4.76)	4.10E-02	2.18	(1.01-4.70)	4.6E-02

#### Interactions

DCC <sub>5</sub> * FYN <sub>1</sub>	17.01 (3.06-94.59)	1.20E-03	17.26 (3.11-95.80)	1.1E-03
EPHB1 <sub>1</sub> * EPHB1 <sub>4</sub>	3.82 (1.39-10.48)	9.30E-03	3.85 (1.41-10.57)	8.7E-03
PLXNC1 <sub>1</sub> * PLXNA2 <sub>2</sub>	29.53 (1.82-478.49)	1.70E-02	29.88 (1.83-486.68)	1.7E-02
RRAS2* SEMA5A <sub>2</sub>	4.85 (1.44-16.33)	1.10E-02	4.78 (1.42-16.14)	1.2E-02
SLIT3 <sub>3</sub> * SEMA5A <sub>2</sub>	15.93 (2.00-127.05)	9.00E-03	15.77 (1.96-126.53)	9.4E-03
RRAS2* EFNA5 <sub>3</sub>	0.03 (0.001-0.67)	2.70E-02	0.03 (0.001-0.66)	2.6E-02

<sup>1</sup> Subscript is used to identify individual SNPs in interactions.

<sup>2</sup> a = log-additive, d = Mendelian dominant, r = Mendelian recessive.

<sup>3</sup> The exceptional difference in OR between the two models must be seen in relation to the large confidence interval. Examination of models with this SNP only suggested no irregularities.